Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda.

"Disclosure: D. J. S. is a founder and board member of AliquantumRx and has stock options. NIAID Safety monitoring Committee (SMC) as Independent safety monitor (ISM). He also received royalties for malaria test reagents from Binax Inc/Inverness Medical. The ethics committees at the Johns Hopkins Bloomberg School of Public Health and the Rwanda Biomedical Center approved the study. The CDC Human Research Protections Office reviewed and approved CDC participation as nonengaged. Written informed consent was obtained from all participants."

"Financial support: This study was made possible by the generous support of the American people through the President’s Malaria Initiative and the United States Agency for International Development under the terms of Cooperative Agreement AID-OAA-A-14-00028. This study was also supported by the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health. The facility was supported in part by Center for AIDS Research (CFAR) 5P30AI094189-04 (Chaisson)."

"We thank Worod Allak at the Becton Dickinson Immunology and Flow Cytometry Core at Johns Hopkins Bloomberg School of Public Health for training, support, and technical assistance using the MagPix. The authors confirm that all ongoing and related trials for this drug/intervention are registered (#NCT03508349). This trial is registered at ClinicalTrials.gov (#NCT03508349, https://clinicaltrials.gov/ct2/show/NCT03508349)."